2022-11-212022-11-212013-04Bayrak, M. vd. (2013). "Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer". Clinical and Translational Oncology, 15(4), 307-312.1699-048Xhttps://doi.org/10.1007/s12094-012-0921-0https://link.springer.com/article/10.1007/s12094-012-0921-0http://hdl.handle.net/11452/29523Overexpression of the gene c-erbB2, which encodes a receptor tyrosine kinase, has been associated with prognosis and response to therapy in several solid tumors. This study was designed to test whether c-erb-B2 overexpression can be related to prognosis of patients with metastatic gastric cancer. Between 2005 and 2010, 46 cases of metastatic gastric cancer were evaluated immunohistochemically for c-erb-B2 overexpression. Overall survival (OS) and time-to-progression (TTP) served as the main outcome measures. c-erbB2 was overexpressed in 19 (41.3 %) cases and 8 patients (17.4 %) had a c-erbB2 score of 3+ (a strong complete membrane staining observed in > 10 % of the tumor cells). c-erbB2 expression was not associated with the clinicohistological characteristics of the study participants. The mean OS was 11.48 +/- A 1.03 months, whereas the mean TTP was 8.28 +/- A 0.8 months. Compared with patients with a score of 2+ or less (n = 38), those with a c-erbB2 score of 3+ (n = 8) had both a significantly lower OS (15.55 +/- A 1.63 vs. 8.22 +/- A 0.88 months, respectively, p < 0.05) and TTP (10.72 +/- A 1.81 vs. 6.11 +/- A 0.61 months, respectively, p < 0.05). After allowance for potential confounders, Cox regression analysis identified a c-erbB2 score of 3+ as an independent predictor of both OS (hazard ratio = 1.9; 95 % confidence interval = 1.1-3.7, p < 0.05) and TTP (hazard ratio = 1.8; 95 % confidence interval = 1.1-4.1, p < 0.05). Our results suggest that c-erbB-2 overexpression may have a prognostic significance in patients with metastatic gastric cancer.eninfo:eu-repo/semantics/closedAccessOncologyC-erbB2Gastric cancerMetastasisImmunohistochemistryPrognosisExpressionTrastuzumabBreastHer2AdultAgedFemaleHumansImmunohistochemistryMaleMiddle agedNeoplasm metastasisPrognosisReceptor, erbB-2Stomach neoplasmsSurvival analysisTumor markers, biologicalUp-regulationYoung adultArticle0003162606000092-s2.0-8487649490130731215422911549OncologyCancer; Trastuzumab; Gastroesophageal JunctionEpidermal growth factor receptor 2AdultAgedArticleC erbB2 geneCancer growthCancer prognosisCancer survivalClinical articleClinical featureControlled studyDisease associationFemaleGene overexpressionHistopathologyHumanHuman tissueMaleMetastasisOverall survivalPredictionScoring systemStomach cancerTime to progression